Literature DB >> 33124044

Are Migraine Patients at Increased Risk for Symptomatic Coronavirus Disease 2019 Due to Shared Comorbidities?

Hayrunnisa Bolay1, Aynur Özge2, Derya Uludüz3, Betül Baykan4.   

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has rapidly transformed the whole world and forced us to look through comorbid diseases and risk factors from a different perspective. COVID-19 shows some inherent risk factors like cardiovascular comorbidities independent from age, gender, and geographic location. One of the most peculiar features of the COVID-19 pandemic is that severe acute respiratory syndrome coronavirus 2 respiratory infections disproportionately impact patients with hypertension, diabetes, and other cardiovascular comorbidities rather than those with allergic respiratory diseases and immune-compromised conditions. Migraine is a complex neuro-vasculo-inflammatory disorder that is also packed frequently with certain medical conditions including vascular disorders, hypertension, allergic diseases such as asthma and systemic inflammatory disorders. Accordingly, 2 different questions arise during the pandemic: (1) Do share comorbidities of cardiovascular diseases and hypertension increase the risk of symptomatic COVID-19 for migraine patients? (2) Do comorbid allergic and atopic diseases, including asthma act as opposite influencers alongside with female gender? This paper focuses on the co-existence of comorbidities of COVID-19, in comparison with migraine, based on a wide clinical dataset and available reports. Discussed mechanisms include potential strategic roles of angiotensin-converting enzyme 2, angiotensin-II, and nucleotide oligomerization domain-like receptor family, pyrin domain containing 3 inflammasome, playing remarkable parts in the pathogenesis of COVID-19 and migraine. There are also some clues about the importance of endothelial and pericyte dysfunction and neuroinflammation in COVID-19 infection, related to complications and survival of the patients. The large epidemiological studies as well as basic research, focusing on migraine patients with COVID-19 will clarify these vital questions during the upcoming periods.
© 2020 American Headache Society.

Entities:  

Keywords:  comorbid disorders; coronavirus disease 2019; migraine; nucleotide oligomerization domain-like receptor family; pericytes; pyrin domain containing 3 inflammasome

Mesh:

Year:  2020        PMID: 33124044     DOI: 10.1111/head.13998

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  6 in total

1.  Navigating migraine care through the COVID-19 pandemic: an update.

Authors:  Heather Angus-Leppan; Angelica E Guiloff; Karen Benson; Roberto J Guiloff
Journal:  J Neurol       Date:  2021-05-17       Impact factor: 4.849

Review 2.  Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19).

Authors:  Biyan Nathanael Harapan; Hyeon Joo Yoo
Journal:  J Neurol       Date:  2021-01-23       Impact factor: 4.849

3.  Latent class cluster analysis identified hidden headache phenotypes in COVID-19: impact of pulmonary infiltration and IL-6.

Authors:  Ömer Karadaş; Bilgin Öztürk; Ali Rıza Sonkaya; Bahar Taşdelen; Aynur Özge; Hayrunnisa Bolay
Journal:  Neurol Sci       Date:  2021-02-09       Impact factor: 3.307

4.  Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-19.

Authors:  Karl Messlinger; Winfried Neuhuber; Arne May
Journal:  Cephalalgia       Date:  2021-08-18       Impact factor: 6.292

Review 5.  Migraine and neuroinflammation: the inflammasome perspective.

Authors:  Oguzhan Kursun; Muge Yemisci; Arn M J M van den Maagdenberg; Hulya Karatas
Journal:  J Headache Pain       Date:  2021-06-10       Impact factor: 7.277

6.  Previous History of Migraine Is Associated With Fatigue, but Not Headache, as Long-Term Post-COVID Symptom After Severe Acute Respiratory SARS-CoV-2 Infection: A Case-Control Study.

Authors:  César Fernández-de-Las-Peñas; Víctor Gómez-Mayordomo; David García-Azorín; Domingo Palacios-Ceña; Lidiane L Florencio; Angel L Guerrero; Valentín Hernández-Barrera; María L Cuadrado
Journal:  Front Hum Neurosci       Date:  2021-06-28       Impact factor: 3.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.